Breaking News Instant updates and real-time market news.

MRNS

Marinus Pharmaceuticals

13:18
11/22/16
11/22
13:18
11/22/16
13:18

Sofinnova reduces stake in Marinus Pharmaceuticals to 4% from 7%

  • 29

    Nov

MRNS Marinus Pharmaceuticals

06/14/16
JEFF
06/14/16
NO CHANGE
Target $2.5
JEFF
Buy
Marinus price target lowered to $2.50 from $13 at Jefferies
Jefferies analyst Brian Abrahams cut his price target for Marinus Pharmaceuticals to $2.50 from $13 after ganaxolone failed in a late-stage seizure study. The analyst, however, still sees residual value for the company given ganaxolone evidence of activity and consistent on-target safety profile. He thinks shares could rebound to $2.50 and keeps a Buy rating on Marinus.
06/14/16
RBCM
06/14/16
DOWNGRADE
RBCM
Sector Perform
Marinus Pharmaceuticals downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Marinus after the company announced that its first Phase 3 epilepsy study for adult focal onset seizures failed to meet its primary endpoint. Target to $2 from $14.
06/20/16
LEER
06/20/16
NO CHANGE
Target $66
LEER
Outperform
Leerink remains positive on SAGE Therapeutics ahead of data catalysts
After meeting with SAGE Therapeutics' (SAGE) CEO Jeff Jonas and CFO Kimi Iguchi, Leerink analyst Paul Matteis says he continues to see a positive risk and reward for the company's stock ahead of multiple near-term data catalysts. Additionally, the analyst says he views the recent failure of Marinus Pharmaceuticals' (MRNS) ganaxolone in focal onset seizures as likely due to a bioavailability issue, not a mechanistic deficiency, and thus shouldn't read negatively on the potential of SAGE Therapeutics' SAGE-217. Matteis reiterates an Outperform rating and $66 price target on SAGE's shares.
09/30/16
JMPS
09/30/16
NO CHANGE
JMPS
Marinus Pharmaceuticals data positive, says JMP Securities
JMP Securities analyst Jason Butler says that a trial of Marinus' ganaxolone PCDH19 in female pediatric eplilepsy yielded "promising" results. The analyst says that the data is positive, while female pediatric eplilepsy is an unmet need. Butler keeps a $5 price target and Outperform rating on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.